Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MicroTech Medical (Hangzhou) Co., Ltd. Class H ( (HK:2235) ) has issued an announcement.
MicroTech Medical (Hangzhou) Co., Ltd. has announced a change in the utilization of its remaining unutilized proceeds from its Global Offering and an extension of the expected timetable for their use. The company plans to fully utilize the funds by December 31, 2027, to further develop its core product through clinical trials, expand its global commercialization capabilities, and enhance its manufacturing capacity. This strategic move is expected to strengthen the company’s market position and operational capabilities.
The most recent analyst rating on (HK:2235) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.
More about MicroTech Medical (Hangzhou) Co., Ltd. Class H
MicroTech Medical (Hangzhou) Co., Ltd. is a company based in China, specializing in medical technology. The company focuses on developing and commercializing medical products, particularly in the area of diabetes management. It aims to expand its market presence globally through clinical trials, registration in major markets, and enhancing its commercialization capabilities.
Average Trading Volume: 327,717
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.81B
See more data about 2235 stock on TipRanks’ Stock Analysis page.